Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology - 1 Jan 2000

Gecgel Karaca Kaan, Muduroglu Mustafa, Erdogan Suat

Abstract excerpt

PURPOSE: Androgen deprivation therapy (ADT) is one of the main strategies to treat prostate cancer (PCa) at various stages of its development. Androgen receptor (AR) antagonists such as enzalutamide are mainstay treatments for castration-sensitive prostate cancer. Though, a majority of patients initially respond to ADT, most will eventually progress to castrate-resistant, due to the development of different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Naphthalenes

Share to Nitriles

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Telomerase

Source

Identifiers

PMID: 29332354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.PMID 29332354Read ↗

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathwaySemantic proximity Read ↗

Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.Semantic proximity Read ↗

A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effectsSemantic proximity Read ↗

High-Dose-Androgen-Induced Autophagic Cell Death to Suppress the Enzalutamide-Resistant Prostate Cancer Growth Via Altering the circRNA-BCL2/miRNA-198/AMBRA1 SignalingSemantic proximity Read ↗

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity Read ↗

Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agentsSemantic proximity Read ↗

Tubulin-Targeted Agents Including Docetaxel and CabazitaxelSemantic proximity Read ↗

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer CellsSemantic proximity Read ↗

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Semantic proximity Read ↗

The effects of telomerase inhibition on prostate tumor‐initiating cellsSemantic proximity Read ↗

Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell deathSemantic proximity Read ↗

Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.